Opus Genetics, Inc. (IRD) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 45.26%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 45.26% | Share-based compensation / revenue. Period ending 2026-06-30. $4.46M ÷ $9.86M × 100 ≈ 45.26% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 9.86M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 4.46M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -50.61M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $9.86M | $4.46M | $-50.61M | (m) | (m) | 45.26% | (m) | (m) |
| 2026-03-31 | (m) | $11.98M | $3.95M | $-43.03M | (m) | (m) | 32.96% | (m) | (m) |
| 2025-12-31 | (m) | $14.20M | $3.40M | $-38.60M | (m) | (m) | 23.94% | (m) | (m) |
| 2025-09-30 | (m) | $14.63M | $3.42M | $-65.17M | (m) | (m) | 23.37% | (m) | (m) |
| 2025-06-30 | (m) | $15.42M | $3.38M | $-64.87M | (m) | (m) | 21.92% | (m) | (m) |
| 2025-03-31 | (m) | $13.65M | $3.29M | $-64.30M | (m) | (m) | 24.10% | (m) | (m) |
| 2024-12-31 | (m) | $10.99M | $3.36M | $-62.07M | (m) | (m) | 30.59% | (m) | (m) |
| 2024-09-30 | (m) | $8.38M | $3.28M | $-29.47M | (m) | (m) | 39.11% | (m) | (m) |
| 2024-06-30 | (m) | $16.45M | $3.08M | $-15.08M | (m) | (m) | 18.69% | (m) | (m) |
| 2024-03-31 | (m) | $19.01M | $3.69M | $-12.14M | (m) | (m) | 19.42% | (m) | (m) |
| 2023-12-31 | (m) | $19.05M | $3.51M | $-10.56M | $0.00 | (m) | 18.43% | (m) | Reported |
| 2023-09-30 | (m) | $57.21M | $3.22M | $29.08M | $0.00 | (m) | 5.63% | (m) | Reported |
| 2023-06-30 | (m) | $45.27M | $3.14M | $18.15M | $0.00 | (m) | 6.94% | (m) | Reported |
| 2023-03-31 | (m) | $41.60M | $2.17M | $18.60M | $4.00K | (m) | 5.21% | 4650.75× | Reported |
| 2022-12-31 | (m) | $39.85M | $1.81M | $18.23M | $9.00K | (m) | 4.53% | 2025.11× | Reported |
| 2022-09-30 | (m) | $0.00 | $1.86M | $-22.13M | $11.00K | (m) | (m) | -2012.18× | Reported |
| 2022-06-30 | (m) | $489.00K | $1.85M | $-21.83M | $11.00K | (m) | 377.71% | -1984.36× | Reported |
| 2022-03-31 | (m) | (m) | $1.86M | $-24.03M | $7.00K | (m) | (m) | -3432.43× | Reported |
| 2021-12-31 | (m) | $589.00K | $1.91M | $-22.70M | $2.00K | (m) | 324.96% | -11352.50× | Reported |
| 2021-09-30 | (m) | (m) | $1.95M | $-30.58M | $5.42M | (m) | (m) | -5.64× | Reported |
| 2021-06-30 | (m) | (m) | $2.09M | $-28.29M | $5.60M | (m) | (m) | -5.05× | Reported |
| 2021-03-31 | (m) | (m) | $1.94M | $-22.42M | $6.29M | (m) | (m) | -3.56× | Reported |
| 2020-12-31 | (m) | (m) | $1.51M | $-19.97M | $6.85M | (m) | (m) | -2.92× | Reported |
| 2020-09-30 | $1.29M | (m) | $279.61K | $-6.43M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $2.27M | (m) | $313.47K | $-7.20M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $3.69M | (m) | $372.05K | $-7.84M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $5.48M | (m) | $456.75K | $-11.22M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $7.75M | (m) | $762.47K | $-14.17M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $9.51M | (m) | $953.26K | $-16.58M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $11.29M | (m) | $1.09M | $-18.59M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $13.11M | (m) | $1.23M | $-20.54M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $13.64M | (m) | $1.10M | $-20.47M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $13.40M | (m) | $1.05M | $-20.00M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $12.51M | (m) | $1.07M | $-19.29M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $10.72M | (m) | $1.04M | $-17.35M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $9.54M | (m) | $1.14M | $-16.38M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $9.19M | (m) | $1.28M | $-15.87M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $8.88M | (m) | $1.34M | $-15.50M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $10.09M | (m) | $1.41M | $-16.41M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $10.92M | (m) | $1.33M | $-16.86M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $11.73M | (m) | $1.19M | $-17.80M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $12.72M | (m) | $1.11M | $-18.71M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $12.15M | (m) | $1.04M | $-18.26M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $11.45M | (m) | $954.40K | $-17.75M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $10.17M | (m) | $892.28K | $-16.23M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $8.64M | (m) | $752.83K | $-14.92M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $7.02M | (m) | $608.79K | $-13.27M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | $5.79M | (m) | $495.45K | $-11.75M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $4.75M | (m) | $399.97K | $-10.43M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $3.97M | $0.00 | $321.83K | $-8.84M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $3.25M | $0.00 | $565.43K | $-7.98M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | $2.52M | (m) | $522.49K | $-6.69M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $2.81M | (m) | $515.38K | $-6.67M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $2.90M | (m) | $511.76K | $-6.60M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $3.39M | (m) | $230.99K | $-6.58M | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | $4.61M | (m) | $327.89K | $-7.94M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $5.92M | $0.00 | $408.37K | $-9.49M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | $10.32M | $0.00 | $527.79K | $-14.10M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $11.99M | $0.00 | $638.61K | $-16.13M | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $3.93M | $0.00 | $584.66K | $-10.31M | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $3.18M | $0.00 | $497.53K | $-6.47M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |